Günther Ofner
CFO & Member of the Management Board

You already saw our main results, and we had a moderate revenue and earnings increase in Q1 ’26. Revenue up 6.1%, EBITDA up 8.2%, and group net profit up 5.3%. We saw overall a positive traffic development in the group with 5.3% plus, especially resulting in strong growth in Malta and Košice. In Vienna, it was 1.6%, including Air India transit passengers in the refueling stops. We saw a positive non-aviation performance, higher de-icing revenues and no winter incentive compared to 2025, which positively contributed to our results. We successfully implemented and are still in the process of implementation of our cost saving and efficiency measures. And I hope we can realize all the plans throughout the year.

Clearly, the Middle East conflict is increasing uncertainty for the coming months. And hopefully, these negative effects will stop very soon. What might be of more importance midterm, at least are the effects of higher fuel costs, which might result in some airline capacity adjustments and also higher ticket prices by many of the carriers to offset these additional costs. Despite all that uncertainty, we can confirm our passenger and financial outlook for 2026 so far. And I hope that the rest of the year will not prove us wrong.

If we move on, you see that our financial results are positive, also reduced by half due to the fact that

India’s foreign direct investment (FDI) inflows increased 17.2% year-on-year to $94.5 billion in 2025-26, aided by overseas investor interest despite global macroeconomic uncertainty and volatile capital flows, according to the Reserve Bank of India‘s latest monthly bulletin.

Gross FDI inflows stood at $94.5 billion in 2025-26 compared with $80.6 billion in the previous year, while net FDI inflows increased sharply to $7.7 billion from $1 billion a year ago.

“On the capital account, gross FDI has been encouraging,” the RBI said, adding that inflows are expected to remain robust amid a recent wave of greenfield investment announcements, particularly in the finance and technology sectors.

The central bank said that March marked the second consecutive month of positive net FDI inflows, despite moderation in gross inflows, aided by lower repatriation and outward FDI. Outward FDI also eased in March, with more than half of the investments directed towards Singapore, the UAE and the Netherlands.

Meanwhile, external commercial borrowings moderated to $43 billion in 2025-26 from $61.2 billion a year earlier, as Indian companies turned cautious on overseas borrowings amid elevated global interest rates and relatively attractive domestic funding conditions.
The RBI also flagged continued pressure from foreign portfolio investor (FPI) outflows. FPIs remained net sellers in April and May amid geopolitical tensions and uncertainty in West Asia, with cumulative outflows of about $10 billion so far in 2026-27, largely from equities.

By Jennifer Nash

Despite a rough start to the week, the S&P 500 rallied in the back half to post its eighth consecutive weekly gain, its longest streak since 2023. Ultimately rising 0.9%, the index is now inches away

Follow

Play Earnings CallPlay Earnings Call

Lyell Immunopharma, Inc. (LYEL) Stifel 2026 Targeted Oncology Virtual Forum May 20, 2026 4:00 PM EDT

Company Participants

Lynn Seely – Principal Executive Officer, President, CEO & Director

Advertisement

Conference Call Participants

Stephen Willey – Stifel, Nicolaus & Company, Incorporated, Research Division

Presentation

Advertisement

Stephen Willey
Stifel, Nicolaus & Company, Incorporated, Research Division

All right. Good afternoon, everyone. I’m Stephen Willey, one of the senior biotech analysts here at Stifel. I’m very glad to have with us in the next session, Lynn Seely, who is the President and CEO of Lyell. Lynn, thanks for joining us. Always appreciate it. Any opening statements you want to make or a brief overview of the company you want to provide before we jump into Q&A?

Lynn Seely
Principal Executive Officer, President, CEO & Director

Advertisement

Sure. I’m happy to give an overview for those who may not be as familiar with Lyell maybe for the record, I should say I’ll be making some forward-looking statements here. So consult our website. But for those of you who don’t know Lyell Immunopharma, we are a cell therapy company, and we’re focused on next-generation cell therapies, both for patients with hematologic malignancies as well as for solid tumors. And we have 2 lead programs in the clinic, both for large markets one in large B-cell lymphoma, where we intend to displace the currently approved CD19 CARs, which have a $3 billion and growing marketplace. And then the second, very novel CAR for metastatic colorectal cancer. So I look forward to telling you about those. / And then I should also just make note of the fact that Lyell is a little bit unique in that we have our own manufacturing like facility where we can launch from that facility and get well into launch with our own manufacturing. So that puts control under our own destiny, which we really like.

This is the forum for daily political discussion on Seeking Alpha. A new version is published every market day.

Please don’t leave political comments on other articles or posts on the site.

The comments below are not regulated with the same rigor as the rest of the site, and this is an ‘enter at your own risk’ area as discussion can get very heated. If you can’t stand the heat… you know what they say…

More on Today’s Markets:

Moderation Guidelines:

We remove comments under the following categories:

• Personal attacks on another user account
• Anti-Vaxxer or covid related misinformation
• Stereotyping, prejudiced or racist language about individuals or the topic under discussion.
• Inciting violence messages, encouraging hate groups and political violence.

Regardless of which side of the political divide you find yourself, please be courteous and don’t direct abuse at other users.

For any issue with regards to comments please email us at : moderation@seekingalpha.com.

Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

This article was written by

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.